This is a good overview of this important area of focus:
Right now, partial reprogramming is the hottest topic in longevity. The field went from being overlooked to becoming one of the most well-funded research areas after billions of dollars in investment into projects like NewLimit (Brian Armstrong) and Altos Labs (Yuri Milner, Jeff Bezos).
But how promising is it exactly? I decided to spend a few months learning all I could in an attempt to answer that question (see detailed notes on all the papers I’ve read here). This deep dive is a culmination of that effort, summarizing what I’ve learned about the current state-of-the-art and limitations of this field.